ArticleJournal of hepatology2021

Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma.

Ruwanthi Kolamunnage-Dona et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.